- The FDA has approved Breyanzi (lisocabtagene maraleucel; liso-cel) from Bristol Myers Squibb (NYSE:BMY) for patients with certain types of large B-cell lymphoma who have not responded to, or who have relapsed after, at least two other types of systemic treatment.
- Breyanzi is the third gene therapy to receive FDA approval for certain types of non-Hodgkin lymphoma, including diffuse large B-cell lymphoma ("DLBCL"), the commonest form of non-Hodgkin lymphoma in adults.
- The tradeable Contingent Value Right (NYSE:BMY.RT) received by Celgene shareholders when the company was acquired by Bristol Myers expired in 2020 as liso-cel failed to win FDA approval by December 31.